Journal of peptide science : an official publication of the European Peptide Society · 2026
Preeclampsia Diagnosis Using β-Hairpin Peptide for ELABELA Detection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghalandari Behafarid, Jessica Jessica, Zhang Qiang, Azmat Mehmoona, Ghorbani Farnaz, Su Wenqiong, Jiang Lai, Ding Xianting
Аннотация
Preeclampsia (PE) poses risks to mothers and infants, especially in low-resource settings. Diagnosis of PE is difficult due to nonspecific symptoms and limited biomarker screening. ELABELA, a circulating peptide hormone and endogenous ligand of the apelin receptor (APJ), has emerged as a promising biomarker for earlier detection of PE, alone or in combination with other biomarkers. Here, we present β-hairpin protein epitope mimetics (BH-PEMs) as a tool for ELABELA detection. Employing an epitope mimetics approach, OP27 from a BH-PEM peptide library emerged as a high-affinity candidate for ELABELA following rational design and screening of a focused peptide library. Experimental assays verified the OP27-ELABELA complex's stability and binding affinity. We successfully detected ELABELA in clinical donor serum samples using the OP27-ELABELA complex-based electrochemical method integrated with electrochemical impedance spectroscopy (EIS), enabling sensitive detection in a complex biological matrix. Our findings establish a proof-of-concept biomarker-driven electrochemical detection strategy for PE, supporting the development of simplified electrochemical diagnostic approaches while highlighting the broader applicability of BH-PEM probes in biomarker detection. The BH-PEM probe demonstrates feasibility for biomarker-driven PE detection and warrants further validation in expanded clinical cohorts, thereby contributing to improved maternal risk assessment and mitigation of health risks for mothers and infants.